10 results on '"Feinstein SB"'
Search Results
2. A retrospective experience of right atrial and superior vena caval thrombi diagnosed by transesophageal echocardiography.
- Author
-
Shapiro MA, Johnson M, and Feinstein SB
- Subjects
- Adult, Aged, Aged, 80 and over, Catheterization, Central Venous adverse effects, Chicago, Diagnosis, Differential, Dialysis adverse effects, Dialysis instrumentation, Female, Heart Diseases etiology, Humans, Kidney Failure, Chronic complications, Kidney Failure, Chronic therapy, Male, Middle Aged, Retrospective Studies, Risk Factors, Staphylococcal Infections diagnosis, Staphylococcal Infections etiology, Superior Vena Cava Syndrome etiology, Thrombosis diagnostic imaging, Thrombosis pathology, Echocardiography, Transesophageal, Heart Atria diagnostic imaging, Heart Atria pathology, Heart Diseases diagnosis, Superior Vena Cava Syndrome diagnosis
- Abstract
Central venous catheter (CVC) thrombosis and infection has become a frequent finding in immunosuppressed and chronically ill medical patients, particularly those with end-stage renal disease. Transesophageal echocardiography (TEE), as the only reliable noninvasive method of imaging the superior vena cava (SVC) is appreciated to be very useful in the evaluation of these lesions. We retrospectively review our findings of TEE for this purpose, with regard to frequency of positive findings, patient characteristics, and microbiologic findings from SVC and right atrial thrombi and vegetations associated with CVCs.
- Published
- 2002
- Full Text
- View/download PDF
3. Contrast echocardiography: current and future applications.
- Author
-
Mulvagh SL, DeMaria AN, Feinstein SB, Burns PN, Kaul S, Miller JG, Monaghan M, Porter TR, Shaw LJ, and Villanueva FS
- Subjects
- Echocardiography, Doppler methods, Humans, Injections, Intravenous, Medical Laboratory Science, Microspheres, Practice Guidelines as Topic, Contrast Media administration & dosage, Echocardiography methods, Image Enhancement
- Abstract
Recent updates in the field of echocardiography have resulted in improvements in image quality, especially in those patients whose ultrasonographic (ultrasound) evaluation was previously suboptimal. Intravenous contrast agents are now available in the United States and Europe for the indication of left ventricular opacification and enhanced endocardial border delineation. The use of contrast enables acquisition of ultrasound images of improved quality. The technique is especially useful in obese patients and those with lung disease. Patients in these categories comprise approximately 10% to 20% of routine echocardiographic examinations. Stress echocardiography examinations can be even more challenging, as the image acquisition time factor is critically important for accurate detection of coronary disease. Improvements in image quality with intravenous contrast agents can facilitate image acquisition and enhance delineation of regional wall motion abnormalities at the peak level of exercise. Recent phase III clinical trial data on the use of Optison and several other agents (currently under evaluation) have revealed that for approximately half of patients, image quality substantively improves, which enables the examination to be salvaged and/or increases diagnostic accuracy. For the "difficult-to-image" patient, this added information results in (1) enhanced laboratory efficiency, (2) a reduction in downstream testing, and (3) possible improvements in patient outcome. In addition, substantial research efforts are underway to use ultrasound contrast agents for assessment of myocardial perfusion. The detection of myocardial perfusion during echocardiographic examinations will permit the simultaneous assessment of global and regional myocardial structure, function, and perfusion-all of the indicators necessary to enable the optimal noninvasive assessment of coronary artery disease. Despite the added benefit in improved efficacy of testing, few data exist regarding the long-term effectiveness of these agents. Currently under evaluation are the clinical and economic outcome implications of intravenous contrast agent use for daily clinical decision making in a variety of patient subsets. Until these data are known, this document offers a preliminary synthesis of available evidence on the value of intravenous contrast agents for use in rest and stress echocardiography. At present, it is the position of this guideline committee that intravenous contrast agents demonstrate substantial value in the difficult-to-image patient with comorbid conditions limiting an ultrasound evaluation of the heart. For such patients, the use of intravenous contrast agents should be encouraged as a means to provide added diagnostic information and to streamline early detection and treatment of underlying cardiac pathophysiology. As with all new technology, this document will require updates and revisions as additional data become available.
- Published
- 2000
- Full Text
- View/download PDF
4. Contrast echocardiography displays increased subendocardial perfusion after nitroglycerin administration.
- Author
-
Chandwaney RH, Zajac E, Saldivar J, Block RJ, Winkelmann J, Malhotra V, Rabor D, Kenner MD, and Feinstein SB
- Subjects
- Angina Pectoris diagnostic imaging, Angina Pectoris drug therapy, Angina Pectoris physiopathology, Blood Pressure drug effects, Endocardium physiopathology, Female, Humans, Male, Middle Aged, Contrast Media, Coronary Circulation drug effects, Echocardiography, Iopamidol, Nitroglycerin pharmacology
- Abstract
A mechanism proposed to contribute to the antianginal effect of nitroglycerin is a redistribution of coronary blood flow to the subendocardium. Contrast echocardiography combines ultrasound with echogenic contrast agents to assess regional myocardial perfusion. This study aims to assess the effect of nitroglycerin on myocardial transmural perfusion with contrast echocardiography in humans. Nine patients scheduled for coronary angiography received 300 microg intracoronary nitroglycerin. Contrast echocardiographic studies were performed before and immediately after the administration of intracoronary nitroglycerin. Videodensitometric analysis was performed off-line to measure subendocardial and subepicardial opacification. Subendocardial opacification greater than subepicardial opacification increased from six of 13 patients before nitroglycerin administration to 11 of 13 after nitroglycerin administration (p <0.05). Similarly, these observations increased from nine of 13 patients to 13 of 13 after nitroglycerin administration during diastole (p <0.05). Contrast echocardiography demonstrates increased subendocardial perfusion after the administration of nitroglycerin in these patients.
- Published
- 1997
- Full Text
- View/download PDF
5. Reduced forward output states affect the left ventricular opacification of intravenously administered Albunex.
- Author
-
Gandhok NK, Block R, Ostoic T, Rawal M, Hickle P, Devries S, and Feinstein SB
- Subjects
- Adult, Aged, Aged, 80 and over, Atrial Fibrillation diagnostic imaging, Female, Humans, Hypertension, Pulmonary diagnostic imaging, Injections, Intravenous, Male, Middle Aged, Mitral Valve Insufficiency diagnostic imaging, Retrospective Studies, Tricuspid Valve Insufficiency diagnostic imaging, Albumins administration & dosage, Contrast Media administration & dosage, Echocardiography, Heart Ventricles diagnostic imaging
- Abstract
Albunex is an Food and Drug Administration-approved ultrasound contrast agent used for the enhancement of left ventricular endocardial borders. To determine the efficacy of intravenously administered Albunex with regard to left ventricular opacification (LVO), a retrospective analysis of 117 patients who received 202 injections of Albunex for enhancement of endocardial borders was done (dose 0.08 to 0.22 ml /kg). Patients were routinely referred to our echocardiography laboratory for stress echocardiography for standard indications. Optimized settings for contrast enhancement (3.5 MHz transducer frequency and maximum dynamic range) were used. Four observers graded LVO on a scale from 0 to 3 (0 = no Albunex seen in the ventricular cavity; 3 = Albunex densely seen in the ventricular cavity). Overall, LVO was reported in 166 (82%) of 202 injections or in 91 (78%) of 117 patients. A significant reduction in LVO was noted in patients with mitral regurgitation, tricuspid regurgitation, atrial fibrillation, systolic dysfunction, or pulmonary hypertension (increased pulmonary artery systemic pressure). LVO was seen in 88% of the patients without these conditions. However, only 12 (44%) of 27 patients with one or more of the above conditions had LVO (p < 0.05). LVO can be achieved in the majority of patients after intravenously administered Albunex when imaged with optimal transducer settings. A subset of patients with systolic dysfunction, mitral regurgitation, tricuspid regurgitation, atrial fibrillation, or increased pulmonary artery systemic pressure has less effective LVO with Albunex. Heart disease associated with decreased forward flow appears to be associated with diminished LVO.
- Published
- 1997
- Full Text
- View/download PDF
6. Optimizing albunex in the left ventricle: an analysis of the technical parameters of four ultrasound systems in canines and humans.
- Author
-
Block RJ, Brodsky L, Ostoic T, Fernandez A, Hickle P, Devries S, Bieniarz T, In M, and Feinstein SB
- Subjects
- Animals, Dogs, Humans, Transducers, Albumins, Contrast Media, Echocardiography methods, Heart Ventricles diagnostic imaging, Image Enhancement
- Abstract
Albunex, an intravascular ultrasound contrast agent, has been used clinically to enhance echocardiographic images. The purpose of this study if (1) to determine whether varying the settings on commercially available ultrasound machines has an effect on left ventricular opacification after intravenously administered Albunex and if there is an effect on left ventricular opacification and (2) to determine the ideal settings for each ultrasound scanner. Six canine hearts were imaged with 1 ml injections of intravenously administered Albunex while varying the transducer frequency, preprocessing curves, postprocessing curves, and dynamic range on a variety of ultrasound units. Subsequently 50 human subjects underwent imaging with the various machines while the dynamic range and transducer frequencies were altered. All subjects received two or three intravenous injections of 10 ml Albunex. The opacification of the left ventricular cavitary images in both parts of the study were interpreted visually on a scale of 0 to 4 (0 = none, 1 = trace, 2 = moderate, 3 = dense, and 4 = ideal) by four observers. The maximum compression and transducer frequency of 3.5 MHz showed significant improvement of left ventricular opacification in both canines and humans. These studies have shown that (1) varying the ultrasound unit's parameters affects the quality of left ventricular imaging when Albunex is used to enhance the image, and (2) higher compression and a transducer frequency of 3.5 MHz tend to enhance Albunex images of canine and human hearts.
- Published
- 1996
- Full Text
- View/download PDF
7. Pitfalls in quantitative contrast echocardiography: the steps to quantitation of perfusion.
- Author
-
Wiencek JG, Feinstein SB, Walker R, and Aronson S
- Subjects
- Albumins, Blood Flow Velocity physiology, Contrast Media, Coronary Vessels diagnostic imaging, Humans, Microcirculation diagnostic imaging, Microcirculation physiology, Models, Biological, Perfusion, Echocardiography methods
- Abstract
Current methods used clinically to assess myocardial perfusion are invasive and expensive. As the technology of ultrasound imaging improves, CE may provide a relatively inexpensive, noninvasive means of quantitating myocardial perfusion. Issues regarding stability of microbubble contrast agents must be studied more closely under physiologic conditions. As such, encapsulated microbubbles may provide more stability under physiologic pressures than free gas microbubbles. Introducing high concentrations of contrast, either by hyperconcentrating the contrast agent or by increasing the injection rate, may provide greater stability under physiologic conditions. Further, before quantitative statement of tissue perfusion can be made, the relationship between tracer concentration and system response must be established. Further, a "linear" postprocessing ultrasound setting does not eliminate this requirement as data must still undergo nonlinear transformation during log compression and time-gain compensation. Additionally, issues regarding "electronic thresholding" must be explored more extensively in vivo. Commercial ultrasound scanners, in their present form, may not offer adequate sensitivity for absolute quantitative studies. Further development of modified ultrasound systems may provide sufficient sensitivity for quantitative perfusion imaging. CE offers a potentially powerful tool in the clinical management of patients with ischemic heart disease. Conventional coronary angiography provides information on the size of a lesion, but accompanying tissue perfusion distal to the lesion cannot be determined. Doppler ultrasonography determines velocity of blood flow in large vessels but does not offer the potential to quantitate tissue perfusion. Clearly, CE has a place in the future of diagnostic imaging. The recent work of Ito et al. demonstrated the qualitative potential of CE in the identification of "areas at risk" in patients who had undergone thrombolysis or percutaneous transluminal coronary angioplasty after an acute myocardial infarction. With further improvement in the ultrasound imaging techniques and microbubble stability, CE may offer an inexpensive, noninvasive means of assessing myocardial perfusion.
- Published
- 1993
- Full Text
- View/download PDF
8. In vitro calculation of flow by use of contrast ultrasonography.
- Author
-
Heidenreich PA, Wiencek JG, Zaroff JG, Aronson S, Segil LJ, Harper PV, and Feinstein SB
- Subjects
- Albumins, Models, Structural, Rheology, Contrast Media, Ultrasonography
- Abstract
Contrast echocardiography has been used for qualitative assessment of cardiac function, and its potential for quantitative assessment of blood flow is being explored. With the development of an ultrasound contrast agent capable of passage through the microcirculation, a mathematical model based on classic dye dilution theory, and a digital ultrasound acquisition system, absolute quantitation of myocardial perfusion may be feasible. This study validates the mathematical model in a simple in vitro tube system. Flow was delivered at variable rates through an in vitro tube system while a longitudinal section was imaged with a modified commercial ultrasound scanner. Albunex contrast agent was injected, and videointensity data were captured and analyzed off line. Time-intensity curves were generated, and flow was calculated by use of a mathematical model derived from classic dye dilution mathematics. For 39 different flow rates, ranging for 9.2 to 110 ml/seconds, a correlation coefficient of r = 0.928 (p < 0.001) with a slope of 0.97 was calculated. We conclude that (1) contrast ultrasonography is capable of quantitative determination of flow in an in vitro system, and (2) a mathematical model based on dye dilution theory can be used to calculate flow with accuracy and precision.
- Published
- 1993
- Full Text
- View/download PDF
9. The influence of intravenous Albunex injections on pulmonary arterial pressure, gas exchange, and left ventricular peak intensity.
- Author
-
Walker R, Wiencek JG, Aronson S, Zaroff J, Glock D, Thisted R, and Feinstein SB
- Subjects
- Albumins administration & dosage, Animals, Dogs, Heart Atria, Heart Ventricles diagnostic imaging, Injections, Injections, Intra-Arterial, Injections, Intravenous, Microspheres, Oxygen blood, Particle Size, Pulmonary Artery physiology, Serum Albumin administration & dosage, Signal Processing, Computer-Assisted, Albumins pharmacology, Blood Pressure drug effects, Contrast Media, Echocardiography methods, Pulmonary Artery drug effects, Pulmonary Gas Exchange drug effects, Ventricular Function, Left drug effects
- Abstract
Contrast ultrasonography may be used to assess regional tissue perfusion. The purpose of this study was to evaluate the safety and efficacy of a new, commercially prepared ultrasound contrast agent (Albunex) in dogs. The injections were administered from peripheral intravenous (IV), right atrial (RA), and pulmonary artery (PA) sites. Acute pulmonary hemodynamic and gas exchange effects of low-dose (0.5, 1.0, 2.0 ml) Phase I injections, and high-dose (2.0, 5.0, 10, 20 ml) Phase II injections of Albunex were evaluated in nine dogs. Immediately before and after each injection, pulmonary artery pressure (PAP) and oxygen tension (PO2) were determined. In addition, left ventricular cavity opacification was assessed visually and by videodensitometric off-line analysis. Visual assessment was performed by four blinded observers who graded on a scale of 0 to 3 (0 = no contrast enhancement of the left ventricular (LV) cavity; 1 = weak or suboptimal contrast enhancement; 2 = optimal or excellent contrast enhancement; and 3 = attenuation of the ultrasound signal following a contrast injection). Peak pixel intensity was also determined with videodensitometric analysis. Results showed that significant changes in PAP or PO2 were not noted after Albunex injections, regardless of injection site or dose range. The average change in PAP after Albunex injection was 1.0 mm Hg +/- 1.2 mm Hg (NS), and the average change in PO2 after Albunex injections was 6.2 mm Hg +/- 6.7 mm Hg (NS). The left ventricular cavity peak pixel intensity was dependent on both injection site (PA = RA > IV) and dose range (2.0 = 1.0 > 0.5).(ABSTRACT TRUNCATED AT 250 WORDS)
- Published
- 1992
- Full Text
- View/download PDF
10. Sonicated echocardiographic contrast agents: reproducibility studies.
- Author
-
Feinstein SB, Keller MW, Kerber RE, Vandenberg B, Hoyte J, Kutruff C, Bingle J, Fraker TD Jr, Chappell R, and Welsh AH
- Subjects
- Air, Lasers, Particle Size, Reproducibility of Results, Sonication, Contrast Media, Echocardiography methods
- Abstract
This article describes the production, analysis, and reproducibility of forming microbubbles for contrast ultrasound imaging. The sonication method used to generate microbubbles was tested by four independent observers, and a subsequent laser particle counter analysis of microbubble size and concentration determined the reproducibility of the method. The results indicated that the mean bubble size was 3.3 +/- 1.2 microns for the entire group, based on three trials of each of the four participants. The characteristics of the bubble size of the microbubbles between observers were assessed with a Poisson distribution with the reproducibility based on the sample mean for each observer's trials. Standardization and calibration of the laser particle counter was accomplished with commercially available latex spheres, sonicated albumin microspheres, and a Coulter counter analysis. Our results indicate that the sonication technique generates small microbubbles with a reproducible uniform size distribution. The method of microbubble production is reproducible and can be widely applied for use in contrast echocardiographic perfusion imaging of tissue in a variety of research and clinical studies.
- Published
- 1989
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.